Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.
|Summary Toggle Feb 27, 2018 1:30 PM PST||
Veracyte Fourth Quarter and Full Year 2017 Financial Results Webcast
|Summary Toggle Feb 14, 2018 2:00 PM EST||
LEERINK Partners 7th Annual Global Healthcare Conference
Bonnie H. Anderson
Chief Executive Officer and Chairman of the Board
Veracyte Investor Presentation, January 2018